Ardelyx, Inc. Stock price

Equities

ARDX

US0396971071

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
9.34 USD +0.21% Intraday chart for Ardelyx, Inc. +7.60% +50.65%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 211M Sales 2025 * 364M Capitalization 2.17B
Net income 2024 * -106M Net income 2025 * - EV / Sales 2024 * 10.3 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 5.97 x
P/E ratio 2024 *
-20.9 x
P/E ratio 2025 *
2,177 x
Employees 267
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.25%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.21%
1 week+7.60%
Current month+0.21%
1 month+0.54%
3 months+96.22%
6 months+93.78%
Current year+50.65%
More quotes
1 week
8.58
Extreme 8.58
9.76
1 month
8.16
Extreme 8.16
10.13
Current year
5.92
Extreme 5.92
10.13
1 year
3.16
Extreme 3.16
10.13
3 years
0.49
Extreme 0.4902
10.13
5 years
0.49
Extreme 0.4902
10.13
10 years
0.49
Extreme 0.4902
35.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 09-02-28
Director of Finance/CFO 52 20-06-08
Chief Tech/Sci/R&D Officer 61 20-10-31
Members of the board TitleAgeSince
Director/Board Member 59 15-10-25
Director/Board Member 57 14-02-28
Chairman 58 09-02-28
More insiders
Date Price Change Volume
24-03-01 9.34 +0.21% 4,827,360
24-02-29 9.32 -1.48% 4,570,310
24-02-28 9.46 -2.17% 3,996,084
24-02-27 9.67 +4.09% 6,900,762
24-02-26 9.29 +7.03% 6,208,807

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.34 USD
Average target price
13.31 USD
Spread / Average Target
+42.53%
Consensus
  1. Stock
  2. Equities
  3. Stock Ardelyx, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW